Cuilin Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6931543/publications.pdf

Version: 2024-02-01

		1163117	1372567	
10	174	8	10	
papers	citations	h-index	g-index	
10	10	10	321	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	SREBP1 as a potential biomarker predicts levothyroxine efficacy of differentiated thyroid cancer. Biomedicine and Pharmacotherapy, 2020, 123, 109791.	5.6	13
2	Glucose metabolism-related gene polymorphisms as the risk predictors of type 2 diabetes. Diabetology and Metabolic Syndrome, 2020, 12, 97.	2.7	15
3	Down-regulation of DANCR acts as a potential biomarker for papillary thyroid cancer diagnosis. Bioscience Reports, 2019, 39, .	2.4	34
4	LncRNAs SNHG12 and LINC00152 were associated with progression of patients with papillary thyroid carcinoma. Future Oncology, 2019, 15, 4167-4179.	2.4	8
5	P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas. Oncology Reports, 2018, 39, 501-510.	2.6	46
6	Effect of AMP â€activated protein kinase subunit alpha 2 (PRKAA2) genetic polymorphisms on susceptibility to type 2 diabetes mellitus and diabetic nephropathy in a Chinese population. Journal of Diabetes, 2018, 10, 43-49.	1.8	13
7	Genetic polymorphism contributes to ¹³¹ I radiotherapy-induced toxicities in patients with differentiated thyroid cancer. Pharmacogenomics, 2018, 19, 1335-1344.	1.3	9
8	REST , not REST4 , is a risk factor associated with radiotherapy plus chemotherapy efficacy in glioma. Drug Design, Development and Therapy, 2018, Volume 12, 1363-1371.	4.3	12
9	STK11 rs2075604 Polymorphism Is Associated with Metformin Efficacy in Chinese Type 2 Diabetes Mellitus. International Journal of Endocrinology, 2017, 2017, 1-6.	1.5	8
10	Molecular mechanisms and potential prognostic effects of REST and REST4 in glioma. Molecular Medicine Reports, 2017, 16, 3707-3712.	2.4	16